Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.

ABSTRACT:

Background

The HEPATORCH trial demonstrated that toripalimab combined with bevacizumab significantly prolonged progression-free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC), with an acceptable safety profile. However, its economic implications remain unclear. This study aimed to evaluate the cost-effectiveness of toripalimab plus bevacizumab versus sorafenib monotherapy as first-line treatment for advanced HCC from the Chinese healthcare system perspective.

Methods

Using clinical data from the HEPATORCH trial, a three-state partitioned survival model was constructed to assess the cost-effectiveness of the two treatment strategies over a 10-year horizon. Cost and utility inputs were derived from the publicly available data and publish

SUBMITTER: Li Z 

PROVIDER: S-EPMC12722981 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature